Mepolizumab bulk supplier for pharma manufacturers

Mepolizumab 100 mg/1 mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 100 mg/1 mL

Reference Brands: Nucala (USA/EU)

Mepolizumab is a Respiratory Disorder product available as injection (prefilled syringe) in strengths 100 mg/1 mL. It corresponds to the reference brand Nucala (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Ask About Access

Quick Response Guaranteed | Verified Suppliers

Product Description:

Mepolizumab, marketed under the brand name Nucala, is a humanized monoclonal antibody approved for the treatment of severe eosinophilic asthma. It is indicated as a maintenance therapy for patients aged six years and older who have an eosinophilic phenotype, in combination with other standard asthma medications. In the European Union, mepolizumab is approved as an add-on therapy for adults with severe refractory eosinophilic asthma. The medication works by targeting interleukin-5 (IL-5), a key cytokine responsible for the growth, activation, and survival of eosinophils, which are immune cells that contribute to airway inflammation. By inhibiting IL-5, mepolizumab reduces eosinophil levels, leading to decreased airway inflammation and fewer asthma exacerbations. Clinical studies have demonstrated that mepolizumab significantly lowers the risk of asthma-related hospitalizations and emergency interventions compared to placebo. The drug is administered as a 100 mg subcutaneous injection, typically once every four weeks, using a pre-filled syringe or auto-injector. Mepolizumab is generally well tolerated, with a favorable safety profile, and provides an effective therapeutic option for patients with severe eosinophilic asthma seeking improved disease control and quality of life.

How Mepolizumab is actually supplied

Mepolizumab is a patented innovator medicine. There is no approved generic or biosimilar, which means it cannot be offered on a wholesale, bulk or third party manufacturing basis by us or by anyone else. Any party offering a generic version is offering something that does not lawfully exist, and that is worth treating as a warning rather than an opportunity.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Ask about Mepolizumab supply →

Back to Listing